<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Rask GC</submitter><funding>NCI NIH HHS</funding><pubmed_abstract>Genes encoding the RNA-binding proteins FUS, EWSR1, and TAF15 (FET proteins) are involved in chromosomal translocations in rare sarcomas. FET-rearranged sarcomas are often aggressive malignancies affecting patients of all ages. New therapies are needed. These translocations fuse the 5' portion of the FET gene with a 3' partner gene encoding a transcription factor (TF). The resulting fusion proteins are oncogenic TFs with a FET protein low complexity domain (LCD) and a DNA binding domain. FET fusion proteins have proven stubbornly difficult to target directly and promising strategies target critical co-regulators. One candidate is lysine specific demethylase 1 (LSD1). LSD1 is recruited by multiple FET fusions, including EWSR1::FLI1. LSD1 promotes EWSR1::FLI1 activity and treatment with the </pubmed_abstract><journal>bioRxiv : the preprint server for biology</journal><pagination>2024.05.19.594897</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11142045</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Seclidemstat blocks the transcriptional function of multiple FET-fusion oncoproteins.</pubmed_title><pmcid>PMC11142045</pmcid><funding_grant_id>T32 CA269052</funding_grant_id><pubmed_authors>Cannon MV</pubmed_authors><pubmed_authors>Taslim C</pubmed_authors><pubmed_authors>Theisen ER</pubmed_authors><pubmed_authors>Bayanjargal A</pubmed_authors><pubmed_authors>Selich-Anderson J</pubmed_authors><pubmed_authors>Duncan A</pubmed_authors><pubmed_authors>Crow JC</pubmed_authors><pubmed_authors>Rask GC</pubmed_authors></additional><is_claimable>false</is_claimable><name>Seclidemstat blocks the transcriptional function of multiple FET-fusion oncoproteins.</name><description>Genes encoding the RNA-binding proteins FUS, EWSR1, and TAF15 (FET proteins) are involved in chromosomal translocations in rare sarcomas. FET-rearranged sarcomas are often aggressive malignancies affecting patients of all ages. New therapies are needed. These translocations fuse the 5' portion of the FET gene with a 3' partner gene encoding a transcription factor (TF). The resulting fusion proteins are oncogenic TFs with a FET protein low complexity domain (LCD) and a DNA binding domain. FET fusion proteins have proven stubbornly difficult to target directly and promising strategies target critical co-regulators. One candidate is lysine specific demethylase 1 (LSD1). LSD1 is recruited by multiple FET fusions, including EWSR1::FLI1. LSD1 promotes EWSR1::FLI1 activity and treatment with the </description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 May</publication><modification>2026-05-29T03:15:03.065Z</modification><creation>2026-05-29T03:06:41.893Z</creation></dates><accession>S-EPMC11142045</accession><cross_references><pubmed>38826330</pubmed><doi>10.1101/2024.05.19.594897</doi></cross_references></HashMap>